Research and development

Fresenius focuses its R & D efforts on its core competencies:

  • Dialysis
  • Infusion and nutrition therapies, generic IV drugs, and medical devices
  • Antibody therapies

Apart from products, we are concentrating on developing optimized or completely new therapies, treatment methods, and services. In 2009 we again successfully continued numerous projects and a number of new products were launched.

Expenses on research and development were € 240 million in 2009 (2008: € 479 million, including € 272 million of inprocess R & D activities acquired with APP Pharmaceuticals). We therefore invested about 5 % of our product sales in R & D. This matched the previous year’s figure excluding the in-process R & D activities acquired. The chart shows R & D expenses by segment. In 2009, Fresenius Medical Care increased its R & D spending by 22 %, and Fresenius Kabi by 18 %. In the segment Corporate / Other, € 44 million was spent on R & D at Fresenius Biotech, mostly on the clinical development of trifunctional antibodies. This was slightly above the € 43 million spent in the previous year. Detailed figures are included in the segment reporting here.

As of December 31, 2009, there were 1,421 employees in research and development in the Group (2008: 1,336). Of that number, 494 were employed at Fresenius Medical Care (2008: 427), 829 at Fresenius Kabi (2008: 793), and 98 at Fresenius Biotech (2008: 116).

The table shows a historical comparison of R & D expenses and the number of employees working in R & D.

Our main research sites are in Europe. Production-related R & D activities are also carried out in the United States and in China. Our R & D projects are mainly conducted in-house; external research is commissioned only on a limited scale.

  2009 2008 2007 2006 2005
1 Excluding amortization expenses of € 272 million on in-process R & D activities acquired with APP Pharmaceuticals.
R & D expenses in million € 240 207 1 184 167 149
as % of product sales 4.7 4.7 1 4.9 4.7 4.6
R & D employees 1,421 1,336 999 911 856

  2009 2008 2007 2006 2005
1 Excluding amortization expenses of € 272 million on in-process R & D activities acquired with APP Pharmaceuticals.
R & D expenses in million € 240 207 1 184 167 149
as % of product sales 4.7 4.7 1 4.9 4.7 4.6
R & D employees 1,421 1,336 999 911 856

We now inform you about the R & D activities in our business segments:

Continue reading:
Fresenius Medical Care

QUICKFINDER